Eurazeo Completes Acquisition of Kurma Partners
Deal News | Apr 30, 2025 | Eurazeo
Eurazeo has completed the acquisition of the remaining capital in French asset management company Kurma Partners, marking a significant milestone in its healthcare sector strategy. Initially acquiring a 70.6% majority stake in 2021, Eurazeo has now fully integrated Kurma Partners, who specialize in biotechnology and medical innovation. Kurma Partners boasts nearly €600 million in assets under management and has played a pivotal role in the European healthcare landscape, with a history of successful exits such as Amolyt Pharma and Emergence Therapeutics. Eurazeo has committed nearly €100 million to Kurma's funds and plans to further bolster their growth with its international platform. The acquisition reflects Eurazeo's strategic focus on healthcare, with plans to expand its assets under management in the sector to €3 billion by 2024. This move underscores Eurazeo's ambition to become a leading player in medical innovation across Europe while preserving Kurma Partners' operational independence.
Sectors
- Private Equity
- Biotechnology
- Healthcare
- Asset Management
Geography
- France – Kurma Partners is a French asset management company.
- Europe – The article emphasizes the European healthcare market and Eurazeo’s goals in this region.
Industry
- Private Equity – Eurazeo, the main subject of the article, is a private equity firm executing an acquisition deal.
- Biotechnology – Kurma Partners specializes in biotechnology investments, a key focus area within the article.
- Healthcare – The article discusses investments in healthcare, particularly medical innovation and therapeutic solutions.
- Asset Management – Describes Kurma Partners' role as an asset management company focused on healthcare investments.
Financials
- 100 million – The amount Eurazeo has committed to Kurma Partners' funds since 2021.
- 600 million – Assets under management by Kurma Partners.
- 140 million – The amount involved in the first closing of Kurma Biofund IV.
- 3 billion – Eurazeo's targeted assets under management dedicated to healthcare investments by the end of 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Eurazeo | Buying Company | Company | A global investment company acquiring Kurma Partners to bolster its healthcare sector portfolio. |
| Kurma Partners | Target Company | Company | A French asset management firm specializing in biotechnology and medical innovation investments, acquired by Eurazeo. |
| Amolyt Pharma | Portfolio Company | Company | One of Kurma's portfolio companies that has undergone a successful exit. |
| Emergence Therapeutics | Portfolio Company | Company | Another successful exit from Kurma's portfolio. |
| Still Technologies | Portfolio Company | Company | A portfolio company in the Kurma Partners network. |